Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-06-23
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in
participants with advanced (metastatic and/or unresectable) solid tumors.